Is Covid Booster Safe For Pregnancy

Risk Associated With COVID-19 Infection During Pregnancy

  • COVID-19 infection during pregnancy is associated with increased risk of maternal severe illness, admission to an intensive care unit, mechanical ventilation, and death.
  • There is a known increased risk of complications from COVID-19 in pregnant patients with underlying health conditions (e.g., diabetes, obesity, increasing age, and cardiovascular disease).
  • There is an increased risk of preterm delivery, and there may be an increased risk of stillbirth.
  • There is increased risk of infection and death for certain racial and ethnic populations.
  • None of the COVID-19 vaccines available for use under emergency use authorization or U.S. Food and Drug Administration (FDA) license causes infertility or spontaneous abortion.
  • There is no evidence of adverse maternal or fetal effects from vaccinating pregnant individuals with the COVID-19 vaccine, and a growing body of data demonstrates the safety of such use.
  • Injection site and systemic events (side effects) are common (e.g., pain at the site of injection, fever, muscle pain, joint pain, headaches, fatigue, and other symptoms may be present after vaccination).
    • For pregnant women who experience fever or if desired for other side effects, acetaminophen is advised.
    • These adverse effects are a common feature of the body’s response to the vaccine and the development of antibodies to ward off the COVID-19 infection.
  • Ongoing safety monitoring is occurring through many government and nongovernment programs.
  • For information on the rare risk of thrombosis with thrombocytopenia syndrome, Guillain–Barré syndrome, and myocarditis, see ACOG’s Practice Advisory COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care.
  • Other safety programs include the following:

  • There are limited data available on the efficacy of COVID-19 vaccines in pregnancy, but so far, the vaccines appear to be equally effective in pregnant individuals and nonpregnant individuals.
  • All currently available COVID-19 vaccines have demonstrated high efficacy among their respective clinical trial endpoints.
  • Two doses of mRNA (Pfizer-BioNTech or Moderna) and Novavax vaccines are necessary to achieve protection in immunocompetent individuals.
  • One dose of adenovirus vector vaccine (J&J/Janssen) is necessary to achieve protection.
  • Moderately to severely immunocompromised individuals (i.e., people who have undergone solid organ transplantation or have been diagnosed with conditions that are considered to have an equivalent level of immunocompromise) should receive an additional dose (i.e., an additional primary dose) of COVID-19 vaccine after their initial vaccine or vaccine series. The additional dose should be administered four weeks after the completion of the initial COVID-19 vaccine or vaccine series. For mRNA vaccines, this means immunocompromised individuals need a 3-dose primary series. For J&J/Janssen vaccine, immunocompromised individuals need a 2-dose primary series with the second dose being an mRNA vaccine.
    • Individuals who receive the Novavax COVID-19 vaccine as their primary series are not currently permitted to receive an additional dose using any COVID-19 vaccine.
  • ACOG recommends that pregnant and recently pregnant people up to 6 weeks postpartum receive a bivalent mRNA COVID-19 vaccine booster dose following the completion of their last COVID-19 primary vaccine dose or monovalent booster.
  • COVID-19 vaccines decrease the risk of severe COVID-19 disease.
    • Even if the patient becomes ill after receiving the vaccination, their chances of developing a serious illness are very low.
  • The majority of hospitalized patients are individuals who did not receive a COVID-19 vaccine.
  • “The worry surrounding vaccination during pregnancy is reasonable,” says Dr. Adamczak. “I do understand it. However, it is our responsibility as medical professionals, OBGYNs, and doctors to inform our patients about the significance and value of this vaccine during pregnancy. ”.

    Well before the pandemic began, vaccines were a polarizing topic. The decision to receive the COVID-19 vaccine, however, for some populations, such as pregnant women and nursing mothers, became crucial as a result of the discovery by medical professionals that the vaccine can protect both the pregnant mother and her unborn child.

    Pregnant women who contract COVID-19 have a higher risk of ICU admission — and even death — compared to nonpregnant women, according to research that has identified pregnancy as a risk factor for severe COVID-19. Perinatologist and CEO of Sharp Mary Birch Hospital for Women Joanna Adamczak “The benefit of getting the COVID-19 vaccine and booster, and thus shielding the expectant mother from COVID, outweighs any theoretical risk of potential harm from the vaccine.” Furthermore, this season’s flu vaccination is crucial because it’s forecast to be a particularly bad one and pregnant women are particularly vulnerable to serious complications. ”.

    While Dr. Adamczak concurs with ACOG’s recommendations and urges everyone to consult their physician about their particular situation before deciding whether or not to get vaccinated. She stresses the importance of pregnant women weighing the available information, their exposure risks to COVID-19, and their individual risks for infection and severe disease.

    How COVID-19 can affect an unborn child According to ACOG, studies show that antibodies that protect from COVID-19 infection and severe illness are passed to the fetus when a pregnant person is vaccinated. Additionally, there is no evidence pregnant women or their infants are negatively affected by COVID-19 vaccination — before or after birth — and a growing body of data supports the vaccines’ efficacy and safety.

    Are the COVID-19 bivalent boosters safe throughout pregnancy?

    A bivalent vaccine has been available since September. The bivalent vaccine provides protection against the original virus and the omicron variants BA, in contrast to the original monovalent vaccine. 4 and BA. 5. The Centers for Disease Control advises that everyone over the age of 12 receive the Pfizer or Moderna bivalent booster at least two months after finishing the primary series or at least two months after the final dose of the monovalent booster. It is unclear at this time how effective this booster will be against the emerging omicron subvariants. These recommendations have the support of the Society for Maternal Fetal Medicine for those who are pregnant, recently pregnant, or nursing. Additionally, the Society has stated that any time during pregnancy, including the first trimester, can be used to administer the bivalent booster

    COVID-19 booster vaccines: Advice for pregnant women

    Leave a Comment